VitalConnect

Digital Health · Medical Devices · Cardiac Monitoring

Acquisition

iRhythm agrees to buy cardiac monitor maker VitalConnect for $287.5M

The move pushes a single-product ambulatory monitoring leader into hospital and multi-vitals markets it never touched before.

• iRhythm Holdings signed a definitive agreement to acquire privately held VitalConnect for approximately $287.5 million, split between $237.5 million in cash and $50 million in iRhythm stock.
• VitalConnect makes an FDA-cleared wearable biosensor platform spanning mobile cardiac telemetry and continuous multi-vitals monitoring for hospitals and remote care.
• iRhythm will provide VitalConnect up to $30 million in interim working-capital funding before closing, and owes a $9 million reverse termination fee in specified antitrust scenarios.
• iRhythm expects the deal to be accretive to its revenue growth rate starting in 2027 while still hitting its previously guided 15% adjusted EBITDA margin target that year.
• The acquisition arrives alongside iRhythm's Q2 2026 results showing $224.2 million in revenue, up 20.1% year-over-year for a seventh straight quarter of 20%+ growth.
• The deal marks iRhythm's shift from a single-product ambulatory cardiac monitoring company built around its Zio patch into a multi-modality cardiac intelligence platform spanning inpatient and home care.